EN
Home/United States/Blog/What are the BMI cut-offs for Asian Americans, and do they change GLP‑1 eligibility?
USUnited States Weight and health

What are the BMI cut-offs for Asian Americans, and do they change GLP‑1 eligibility?

What the CDC, FDA labels, ADA, USPSTF and the WHO say about BMI in Asian Americans: where a lower line is settled, where it isn’t, and a worked example in pounds.

GLP Guidebook teamPublished Oct 12, 20268 min read10 sourcesWritten from published sources

Written for the United States. Other country versions are coming.

The short answer

For diabetes screening, US guidance (ADA and USPSTF) uses a lower BMI of 23 for Asian Americans, instead of 25. For GLP‑1 weight medicines, FDA labels and Medicare’s Bridge use the standard lines: 30, or 27 with a weight-related condition. We found no US rule lowering those for Asian Americans.

Key takeaways

  • The ADA’s 2026 Standards of Care advise diabetes testing at a BMI of 23 or more in people of Asian ancestry with a risk factor, against 25 for others.8
  • The FDA labels for Zepbound and Wegovy use a BMI of 30, or 27 with a weight-related condition, with no adjustment for ethnicity.2,3
  • In a study of 1,663 Asian American adults, screening for diabetes only at a BMI of 25 or more would have missed 36% of those who had it.7
  • The ADA’s 2026 obesity section uses 27.5 for Asian Americans only for weight-loss surgery in type 2 diabetes and for obesity in type 1 diabetes.10
  • In STEP 6, East Asian adults lost 13.2% of their weight on Wegovy 2.4 mg against 2.1% on a dummy injection over 68 weeks.3
On this page
  1. What BMI cut-offs do US guidance and labels use?
  2. Why might Asian Americans need a lower cut-off?
  3. Which US guidance uses a lower cut-off, and what is not settled?
  4. Were Asian people in the GLP‑1 trials?
  5. What does this mean if you are Asian American?
  6. Questions people ask
  7. How we researched this

What BMI cut-offs do US guidance and labels use?

For most adults, overweight starts at a BMI of 25 and obesity at 30. The CDC applies those categories “regardless of age, sex, or race”, and the GLP‑1 weight labels use 30, or 27 with a weight-related condition.1,2,3

Before you go further
  • BMI (body mass index) is your weight in kilograms divided by your height in meters squared. Calculators convert from pounds and inches.
  • Guidelines describe; a prescriber decides. Nothing here means you do or don’t qualify for a medicine.
  • This post separates what is settled in US guidance from what is not. Where we found no rule, we say so.
Who sets itCut-offEthnicity adjustment?
CDC adult categoriesOverweight 25 to under 30; obesity 30 or more1None: “regardless of age, sex, or race”1
FDA labels (Zepbound, Wegovy) for weightBMI 30 or more, or 27 to under 30 with at least one weight-related condition2,3None on the label2,3
NIH (NIDDK) guidance on weight medicinesBMI 30 or more, or 27 or more with weight-related health problems4None mentioned4
Medicare GLP‑1 Bridge (a payment rule)BMI 35; or 30 plus named conditions; or 27 plus named conditions5None in CMS’s prescriber sheet5

Why might Asian Americans need a lower cut-off?

Because diabetes and heart risk start at lower BMIs in many Asian populations. A 2004 World Health Organization expert group found the risk point varies from a BMI of 22 to 25 across Asian groups.6

The WHO group said the share of Asian people at high risk of type 2 diabetes and heart disease “is substantial at BMIs lower than” 25.6 But it also said the data “do not necessarily indicate a clear BMI cut-off point for all Asians”, and kept the standard cut-offs as the international classification.6

Instead, it suggested extra “public health action points” at BMIs of 23, 27.5, 32.5 and 37.5, for countries to use when deciding their own lines.6

A US study tested this in Asian Americans. It pooled 1,663 adults aged 45 and over, including South Asian, Japanese American and Filipino community studies.7

  • Screening for diabetes only at a BMI of 25 or more would miss 36% of Asian Americans who had it.7
  • Screening at 23 or more would miss only about 15%.7
  • The authors concluded the cut point for diabetes screening “should be <25 kg/m2, and ≥23 kg/m2 may be the most practical.”7

Which US guidance uses a lower cut-off, and what is not settled?

A lower line of 23 is settled for diabetes screening, and 27.5 for weight-loss surgery in people with diabetes. We found no US rule that lowers the BMI for GLP‑1 weight medicines in Asian Americans.8,9,10

GuidanceLower cut-off for Asian AmericansWhat it is for
ADA Standards of Care 2026, Table 2.5BMI 23 or more, with one or more risk factors8Testing for prediabetes and type 2 diabetes8
USPSTF 2021“A BMI of 23 or greater may be an appropriate cut point”9Diabetes screening at a lower BMI9
ADA 2026, recommendation 8.22BMI 27.5 or more, instead of 3010Considering metabolic (weight-loss) surgery in type 2 diabetes10
ADA 2026, recommendation 8.29BMI 27.5 or more, instead of 3010Defining obesity in adults with type 1 diabetes10

What is not settled. The ADA’s 2026 recommendation on obesity medicines (8.17) says they “should be considered” for people with diabetes and overweight or obesity, with no Asian-specific BMI.10 The FDA labels, NIH guidance and the Medicare Bridge use the standard numbers.2,3,4,5 So a lower BMI can prompt a diabetes test, but it does not by itself change what the label or a plan accepts.

The ADA also says BMI can mislead. It suggests confirming excess body fat with a waist or body-fat measure “particularly in individuals with BMI 25–34.9” and “in certain populations (South Asian individuals)”.10

Free toolCheck your BMI and waist

Works in pounds and inches, and checks waist size too. No sign-up.

Open the BMI and waist tool

Were Asian people in the GLP‑1 trials?

Yes, but as a minority in most. Asian people made up 11% of the main Zepbound weight trial and 13% of the main Wegovy one. One Wegovy trial enrolled only East Asian adults, in Japan and South Korea.2,3

How these trials work: people are split at random, one group gets a dummy injection (placebo), everyone gets the same diet and activity advice, and the gap between groups is what the medicine added. Separate trials can’t be compared directly.

STEP 6Semaglutide 2.4 mg (Wegovy) vs dummy, East Asian adults

401 adults in Japan and South Korea for 68 weeks, all Asian. Entry: BMI 35 or more with one weight-related condition, or BMI 27 to 34.9 with two. Average start weight 193 lb (87.5 kg).3

Weight lost, % of starting weight

Semaglutide 2.4 mg13.2%
Semaglutide 1.7 mg9.6%
Dummy injection2.1%

84 in 100 on 2.4 mg lost at least 5%, against 19 in 100 on the dummy.3

STEP 6 used lower entry BMIs than US trials, but it studied people living in East Asia, not Asian Americans.3 The Zepbound label reports weight loss “irrespective of age, sex, race, ethnicity” in its main trials.2

RisksThe risks, in brief
  • Stomach effects are the most common. In the Wegovy 2.4 mg weight trials, 44 in 100 felt sick against 16 in 100 on a dummy injection.3
  • Pancreatitis and gallbladder problems are label warnings for Wegovy and Zepbound.2,3
  • Kidney injury can follow dehydration from vomiting or diarrhea.2,3
  • Thyroid tumors were seen in rodents; both carry a boxed warning and are not used with a personal or family history of medullary thyroid cancer or MEN 2.2,3
Full detail in our side-effects guide →

What does this mean if you are Asian American?

A BMI of 23 or more is a reason to ask about diabetes testing. Medicine decisions still follow the label criteria, your health conditions and your prescriber’s judgment.2,3,8,9

A worked example. For someone 5 feet 7 inches tall (170 cm), by our arithmetic:

BMIWeight at 5 ft 7 inWhy it matters
23About 147 lb (67 kg)Diabetes screening line for Asian ancestry, with a risk factor8
25About 160 lb (72 kg)Standard overweight line1
27About 172 lb (78 kg)Label line with a weight-related condition2,3
27.5About 176 lb (80 kg)ADA surgery line for Asian Americans with type 2 diabetes10
30About 192 lb (87 kg)Standard obesity line; label line on its own1,2,3
  1. Ask about a diabetes test if your BMI is 23 or more and you have a risk factor such as a parent or sibling with diabetes, high blood pressure or past heart disease. The ADA’s list of risk factors also includes Asian American ancestry itself.8
  2. Ask about a waist measurement. The ADA suggests confirming excess body fat with a waist or body-fat measure, especially in South Asian people.10
  3. Know the label line. For weight-management medicines, the label criteria are BMI 30, or 27 with a weight-related condition.2,3
  4. Check your coverage. Insurers and Medicare’s Bridge set their own BMI rules; we found no ethnicity adjustment in the Bridge rules.5

Questions people ask

What BMI is overweight for Asian Americans?

The CDC uses 25 for all adults. For diabetes screening, the ADA uses 23 or more for people of Asian ancestry with a risk factor.1,8

Do Asian Americans qualify for Wegovy or Zepbound at a lower BMI?

The FDA labels use 30, or 27 with a weight-related condition, with no ethnicity adjustment. We found no US rule lowering that line; a prescriber decides.2,3

Why is BMI 23 used for Asian Americans?

A US study found screening only at 25 would miss 36% of Asian Americans with diabetes; at 23, about 15%.7

Does Medicare’s GLP‑1 Bridge use a lower BMI for Asian Americans?

We found no ethnicity adjustment in CMS’s Bridge prescriber sheet: BMI 35, or 30 or 27 with named conditions.5

What BMI does the ADA use for weight-loss surgery in Asian Americans?

For people with type 2 diabetes, the ADA says to consider metabolic surgery at a BMI of 27.5 or more in Asian American individuals, instead of 30.10

How we researched this

On October 12, 2026, we read the full text of sections 2 and 8 of the ADA Standards of Care in Diabetes—2026, the USPSTF 2021 diabetes screening recommendation, the WHO 2004 expert consultation abstract, the Araneta 2015 study, CDC’s BMI categories, NIDDK’s page on weight medicines, CMS’s Bridge prescriber sheet and the current US Zepbound and Wegovy labels.

Some summaries say the ADA’s 2026 obesity guidance sets Asian American BMI lines for medicines. In the full text we found 27.5 used only for surgery and for type 1 diabetes, so that is all we report. Weights in the example are our arithmetic.

Before you move on

  • CDC and FDA labels use the standard BMI lines for everyone.
  • BMI 23 is a settled US line for diabetes screening in Asian Americans.
  • We found no US rule lowering the BMI for GLP‑1 weight medicines in Asian Americans.
  • A waist measurement can add to BMI, especially for South Asian people.
BMI and waist toolCould it be an option?Should I consider it?

More from the US blog

USUnited StatesDoes Medicare cover Wegovy or Zepbound? The GLP-1 Bridge USUnited StatesGetting Zepbound or Wegovy covered: prior authorization USUnited StatesZepbound vs Wegovy: results, side effects, cost
About GLP Guidebook

The monthly US update

An independent guide to GLP‑1 medicines. We don't sell medicines, take drug-company money or earn clinic commissions. Once a month: FDA approvals and safety notices, label changes, Medicare and Medicaid coverage changes, and published price changes. How we write

Was this post easy to understand?

Sources

  1. Centers for Disease Control and Prevention (CDC). Adult BMI categories. Page last reviewed March 19, 2024. cdc.gov
  2. Eli Lilly. Zepbound (tirzepatide) injection: US prescribing information, revised 08/2026. pi.lilly.com
  3. Novo Nordisk. Wegovy (semaglutide) injection and tablets: US prescribing information and Medication Guide, revised 06/2026. novo-pi.com
  4. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, part of NIH). Prescription medications to treat overweight and obesity. Last reviewed June 2024. niddk.nih.gov
  5. Centers for Medicare & Medicaid Services (CMS). Medicare GLP‑1 Bridge: information for prescribers. CMS Product No. 12235, June 2026. cms.gov
  6. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363(9403):157–63. DOI · PMID 14726171
  7. Araneta MR, Kanaya AM, Hsu WC et al. Optimum BMI cut points to screen Asian Americans for type 2 diabetes. Diabetes Care 2015;38(5):814–20. DOI · PMID 25665815 · PMC4407753
  8. American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes—2026. Diabetes Care 2026;49(Suppl 1):S27–S49, Table 2.5. DOI · PMC12690183
  9. US Preventive Services Task Force. Prediabetes and type 2 diabetes: screening. Final recommendation, August 24, 2021. uspreventiveservicestaskforce.org
  10. American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of diabetes: Standards of Care in Diabetes—2026. Diabetes Care 2026;49(Suppl 1):S166–S182, recommendations 8.2a, 8.17, 8.22, 8.29. DOI · PMC12690172

Last checked Oct 12, 2026 · Next review due Oct 12, 2027 · Report an error

How this post was made. Written by the GLP Guidebook team from the sources above. It's general information, not medical, legal or tax advice. Talk to a qualified doctor, nurse practitioner or pharmacist before starting, stopping or changing any medicine. How we write